PURE Bioscience, Inc. PURE
OTC PK
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 2.32M | 2.42M | 2.41M | 2.35M | 2.20M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.32M | 2.42M | 2.41M | 2.35M | 2.20M |
| Cost of Revenue | 992.00K | 997.00K | 968.00K | 926.00K | 899.00K |
| Gross Profit | 1.33M | 1.43M | 1.44M | 1.43M | 1.30M |
| SG&A Expenses | 3.08M | 3.03M | 3.10M | 3.12M | 3.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.40M | 4.34M | 4.39M | 4.38M | 4.47M |
| Operating Income | -2.08M | -1.92M | -1.98M | -2.02M | -2.27M |
| Income Before Tax | -2.48M | -2.21M | -2.16M | -2.17M | -2.40M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -2.48 | -2.21 | -2.16 | -2.17 | -2.40 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -2.48M | -2.21M | -2.16M | -2.17M | -2.40M |
| EBIT | -2.08M | -1.92M | -1.98M | -2.02M | -2.27M |
| EBITDA | -2.08M | -1.91M | -1.98M | -2.02M | -2.23M |
| EPS Basic | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 465.80M | 446.49M | 447.51M | 447.48M | 447.45M |
| Average Diluted Shares Outstanding | 465.80M | 446.49M | 447.51M | 447.48M | 447.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |